Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026
Basics
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Market cap
171.0B USD
Enterprise value
223.5B USD
Full-time employees
75,000
Overall health
Strength:its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback:growing more slowly than most peersgrowing more slowly than peers
Drawback:higher risk than most peers: less short-term liquidity (current ratio 1.27 vs a peer median of 2.59) and more debt relative to equity (0.74× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.27 vs peers 2.59) and more debt vs equity (0.74× vs peers 0.22×)
Ranks #733 of 1,157 healthcare companies (bottom 37%)
Borrowing rising faster than profit.Since 2022 (an unusually strong year for operating profit): debt +81%, operating profit −60%.Since 2022: debt +81%, operating profit −60%.
Pfizer's debt grew 81% since 2022 while operating profit changed −60%.
Profit below an unusually strong 2022.Since 2022 (an unusually strong year for operating profit): revenue −38%, operating profit −60%.Since 2022: revenue −38%, operating profit −60%.
Since 2022, Pfizer's revenue changed −38% while operating profit fell 60%: costs rose faster than sales.
Cash flow well above reported profit. Free cash flow is 2.5× reported profit.
Free cash flow is 2.5× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Wide margins.Operating margin 22% (12 months to Jun 2026) vs a peer median of 7.1%.Operating margin 22% vs peers 7.1%.
Pfizer keeps 22% of revenue as operating profit, more than 83% of peers (median 7.1%).
Why it changed since the Oct 27, 2026 close: Safety percentile 32 → 33
Peer companies moved+1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Pfizer
Is Pfizer getting weaker?
Its latest SEC filing (Aug 4, 2026) showed no major changes. Its overall score is unchanged at 45/100 since Oct 28, 2026.
How is Pfizer valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 66/100 against 1,393 healthcare peers.EBITDA yield 9.0% vs a peer median of 4.0% (stronger than 78% of peers).EBITDA yield 9.0% vs peers 4.0% (stronger than 78% of peers).
Is Pfizer growing?
More slowly than most of its peers. Growth scores 14/100 against 1,393 healthcare peers.Earnings per share growth -59.8% vs a peer median of 9.8% (weaker than 94% of peers).Earnings per share growth -59.8% vs peers 9.8% (weaker than 94% of peers).
How profitable is Pfizer?
More profitable than most of its peers. Profitability scores 68/100 against 1,393 healthcare peers.Operating margin 21.7% vs a peer median of 7.1% (stronger than 83% of peers).Operating margin 21.7% vs peers 7.1% (stronger than 83% of peers).
How risky is Pfizer?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 0.28 vs a peer median of 0.63 (stronger than 82% of peers).Beta 0.28 vs peers 0.63 (stronger than 82% of peers).Current ratio 1.27× vs a peer median of 2.59× (weaker than 81% of peers).Current ratio 1.27× vs peers 2.59× (weaker than 81% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 28, 2026 · filed Aug 4, 2026 · compared with the quarter ended Mar 29, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
63.3B USD
63.7B USD
+0.6%
Net income (12 months)
7.5B USD
4.3B USD
−42.1%
Operating margin
23.0%
21.7%
−1.3 pts
Free cash flow (12 months)
9.5B USD
11.0B USD
+15.8%
Debt
64.5B USD
63.2B USD
−2.0%
Cash
1.7B USD
976.0M USD
−42.7%
Shares outstanding
5.70B
5.70B
+0.0%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Drug Manufacturers - General companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
62.1%
66.1%
58.1%
71.9%
74.3%
▲ 2.4 pts
Operating margin
23.9%
35.4%
2.1%
19.5%
22.8%
▲ 3.3 pts
Net margin
27.0%
31.0%
3.6%
12.6%
12.4%
▼ 0.2 pts
Return on assets (ROA)
12.1%
15.9%
0.9%
3.8%
3.7%
▼ 0.0 pts
Return on equity (ROE)
28.5%
32.8%
2.4%
9.1%
9.0%
▼ 0.1 pts
Free cash flow margin
36.7%
25.7%
8.0%
15.5%
14.5%
▼ 1.0 pts
Current ratio
1.40×
1.22×
0.91×
1.17×
1.16×
▼ 1.0%
Quick ratio
1.19×
1.00×
0.69×
0.92×
0.87×
▼ 5.1%
Debt to equity
0.50×
0.37×
0.81×
0.73×
0.75×
▲ 2.7%
Interest coverage
15.05×
28.91×
0.58×
4.02×
5.33×
▲ 33%
PFE price history
Price history is added with the daily price update and will appear after the next one.